A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
Recap by typeshit. Full story at CBC.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
Halioua argues dogs beat mice as models because they are genetically diverse, share our environment and develop age-related diseases naturally. No peptide link is stated.
NewsNation reports doctors' guidance on pausing GLP-1 medications ahead of pregnancy. The full story has their reasoning.
The $49 virtual weight management visits now cover insurance checks and Medicare GLP-1 Bridge support, with pharmacists contacting everyone who starts a fill.
Loading…